OncoMatch

OncoMatch/Clinical Trials/NCT07052214

PSMA PET Combined With MRI for the Detection of PCa

Is NCT07052214 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies 68Ga-PSMA-11 for pca.

Phase 3RecruitingTelix Pharmaceuticals (Innovations) Pty LimitedNCT07052214Data as of Sep 2026Location: United States · Australia

Treatment: 68Ga-PSMA-11This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

68Ga-PSMA-11

Cancer type

Prostate Cancer

Biomarker criteria

Allowed: BRCA1 mutation

Known hereditary cancer syndromes (e.g. BReast CAncer gene [BRCA]1/2, Homeobox protein Hox-B13 [HOXB13] mutations)

Allowed: BRCA2 mutation

Known hereditary cancer syndromes (e.g. BReast CAncer gene [BRCA]1/2, Homeobox protein Hox-B13 [HOXB13] mutations)

Allowed: HOXB13 mutation

Known hereditary cancer syndromes (e.g. BReast CAncer gene [BRCA]1/2, Homeobox protein Hox-B13 [HOXB13] mutations)

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Male only

Prior therapy

Cannot have received: pelvic irradiation

Prior pelvic irradiation

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of California Los Angeles · Los Angeles, California
  • University of California San Francisco · San Francisco, California
  • Impression Imaging · Boca Raton, Florida
  • University of Miami · Miami, Florida
  • UroPartners,LLC · Chicago, Illinois

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT07052214 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior pelvic irradiation disqualifies patients from enrollment.

Is this trial open to female patients?

No. This trial enrolls male patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify